Correction to “Astaxanthin Modulates Inflammation in Type 2 Diabetes via Regulation of microRNAs, Lysophosphatidylcholine, and α‐Hydroxybutyrate”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsBiochemical Acid Research Studies · Medicinal Plants and Bioactive Compounds · Sirtuins and Resveratrol in Medicine
A. Sharifi‐Rigi, F. Zal, M.‐H. Aarabi, M. Dehghani, N. Roustaei Rad, and S. Taghiyar, “Astaxanthin Modulates Inflammation in Type 2 Diabetes via Regulation of microRNAs, Lysophosphatidylcholine, and α‐Hydroxybutyrate,” International Journal of Endocrinology 2025, no. 1 (2025): 1–19, https://doi.org/10.1155/ije/5878361.
In the article, there are erroneous values in the text of Section 3.2.3. Additionally, the term “serum urea” is used to refer to Blood Urea Nitrogen (BUN) values; however, to ensure clarity and consistency, serum urea should be read as BUN.
Section 3.2.3 states the following:
“As indicated in Table 1, the baseline urinary ACR, serum urea, creatinine, and uric acid for the participants with ACR ≥ 30 mg/g in the ASX subgroup were 34.46 ± 7.36, 37.63 ± 9.72, 1.3 ± 0.05, and 5.71 ± 1.48, respectively. Consuming ASX capsules on a daily basis substantially reduced (p < 0.05) urinary ACR (p = 0.003), BUN (p = 0.006), Cr (p = 0.009), and uric acid (p = 0.014) to 25.39 ± 8.22, 28.01 ± 8.61, 8.4 ± 0.07, and 4.37 ± 1.93, respectively.”
Section 3.2.3 should read the following:
“As indicated in Table 1, the baseline urinary ACR, BUN, creatinine, and uric acid for the participants with ACR ≥ 30 mg/g in the ASX subgroup were 34.46 ± 7.36, 37.91 ± 9.72, 1.34 ± 0.50, and 5.91 ± 1.48, respectively. Consuming ASX capsules on a daily basis substantially reduced (p < 0.05) urinary ACR (p = 0.003), BUN (p = 0.006), and Cr (p = 0.019) to 28.39 ± 8.22, 29.86 ± 8.61, and 0.99 ± 0.71, respectively. Uric acid also decreased to 5.77 ± 1.93, although this change was not statistically significant (p = 0.814).”
Additionally, Table 1 should be updated to reflect the correct use of the term BUN.
The authors confirm these corrections ensure consistency throughout the manuscript and do not affect the results, discussion, or conclusions of the study.
We apologize for these errors.